Module 4: Drug-resistant tuberculosis treatment
Module 4: Drug-resistant tuberculosis treatment
Table of Content (Online Version) :
- Acknowledgements
- Abbreviations and acronyms
- Definitions
- Executive summary
- Introduction
-
Recommendations
- Section 1. Regimen for rifampicin-susceptible, isoniazid-resistant tuberculosis
- Section 2. Shorter all-oral bedaquiline-containing regimen for multidrug - or rifampicin-resistant tuberculosis
- Section 3. Longer regimens for multidrug- or rifampicin-resistant tuberculosis
- Section 4. The bedaquiline, pretomanid and linezolid (BPaL) regimen for multidrug-resistant tuberculosis with additional fluoroquinolone resistance
- Section 5. Monitoring patient response to MDR-TB treatment using culture
- Section 6. Starting antiretroviral therapy in patients on second-line antituberculosis regimens
- Section 7. Surgery for patients on MDR-TB treatment
- Section 8. Care and support for patients with MDR/RR-TB
-
Research gaps
- Section 1. Regimens for isoniazid-resistant TB
- Section 2. Shorter all-oral bedaquiline-containing regimen for MDR/RR-TB
- Section 3. Longer regimens for MDR /RR-TB
- Section 4. The BPaL regimen for MDR-TB with additional fluoroquinolone resistance
- Section 5. Monitoring patient response to MDR-TB treatment using culture
- Section 6: Starting antiretroviral therapy in patients on secondline antituberculosis regimens
- Section 7. Surgery for patients on MDR-TB treatment
- Section 8. Care and support for patients with MDR-TB
- References
- Supplementary Table
- Online annexes
VIEW PDF VERSION